CI 1040

Known as: CI-1040, CI1040 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2018
051020022018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Though prostate cancer (PCa) has slow progression, the hormone refractory (HRCP) and metastatic entities are substantially lethal… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlotinib is limited by the development of drug… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
OBJECTIVE Abdominal aortic aneurysm (AAA) is a life-threatening disease affecting almost 10% of the population over age 65… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?
2008
2008
The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2007
2007
CONTEXT Targeting MAPK kinase (MEK) in the MAPK pathway is a potentially effective therapeutic strategy for thyroid cancer… (More)
Is this relevant?
2006
2006
Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder that results in neuroectodermal tumors. The NF1 tumor… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD… (More)
Is this relevant?
2005
2005
Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral… (More)
Is this relevant?